Side effects: Freedom of information and the communication of doubt

International Journal of Risk and Safety in Medicine

Volumn 9, Issue 3, 1996, Pages 201-210

  Herxheimer, Andrew ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTODENE;

ARTICLE; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; DRUG SAFETY; HEALTH CARE POLICY; HUMAN; MEDICOLEGAL ASPECT;

EID: 0030434865     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: 10.3233/jrs-1996-9311     Document Type: Article

References (21)

1. W.H.W. Inman, ed., Monitoring for Drug Safety, 2nd edn, MTP, Lancaster, 1986.
2. WHO Anniversary Symposium, Adverse drug reactions: a global perspective on signal generation & analysis, WHO Collaborating Centre for International Drug Monitoring, Uppsala, 1988.
3. H. Fucik and I.R. Edwards, Impact and credibility of the WHO adverse reaction signals, Drug Information Journal 30(2) (1996), 461-464.
4. M. Lindquist, J. Sanderson, C. Claesson, J.-L. Imbs, A. Rohan and I.R. Edwards, New pharmacovigilance information on an old drug. An international study of spontaneous reports on digoxin, Drug Investigation 8(2) (1994), 73-80.
5. The ADR Signals Analysis Project (ASAP) Team (M. Lindquist, M. Pettersson, I. Ralph Edwards, J. Sanderson, N. Taylor, P. Fletcher and J. Schou) and F.T. Fraunfelder, Omeprazole and vision disorders: seeing alternatives, Pharmacoepidemiology and Drug Safety 5 (1996), 27-32.
6. J. Abraham, Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation, UCL Press, London, 1995.
7. F.G. Vaz, R. Singh and M. Nuruzzaman, Hepatitis induced by nomifensine, BMJ 289 (1984), 1268-1269.
8. Editorial. Trouble with nomifensine, Drug and Therapeutics Bulletin 23 (1985), 98-100.
9. P.S. Schönhöfer, Germany: the nomifensine affair, Lancet 338 (1991), 1448.
10. Committee on safety of Medicines, CSM Update: withdrawal of nomifensine, BMJ 293 (1986), 41.
11. M. Verhamme, C. de Wolf-Peters and W. van Steenbergen, Hepatic injury due to glafenine, Neth. J. Med. 27 (1984), 35-39.
12. B.H.C. Stricker et al., Glafenine-associated hepatic injury: analysis of 38 cases and review of the literature, Liver 6 (1986), 63-72.
13. Editorial. Glafénine: précautions d'emploi, Revue Prescrire 10 (1990), 62.
14. A. Herxheimer, Belgium: withdrawal of glafenine, Lancet 337 (1991), 102.
15. Editorial. Revised indications for co-trimoxazole (Septrin, Bactrim, various generic preparations), Current Problems in Pharmacovigilance 21 (1995), 6.
16. British National Formulary No. 11 (1986), 208.
17. H. Jick and L. Derby, Is cotrimoxazole safe? (letter), Lancet 345 (1995), 1118-1119.
18. C. Dollery, ed., Therapeutic Drugs, Churchill Livingstone, Edinburgh, 1991, Vol. 2, S135-136.
19. D. Carnall, Controversy rages over new contraceptive data, BMJ 311 (1995), 1117-1118.
20. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception, Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease, Lancet 346 (1995), 1582-1588.
21. H. Jick, S.S. Jick, V. Gurevich, M.W. Myers and C. Vasilakis, Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components, Lancet 346 (1995), 1589-1593.